EUVIMEDEUVIMED entdecken
BeobachtungsstudieOpen Access · CC BY-NC-ND 4.0

Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome

Yushan He iD, Jie Wu, Chaonan Fan iD, Zheng Li, Jun Liu, Kechun Li, Quan Wang, Suyun Qian iD

Annals of Clinical and Translational Neurology · 2025-09 · 12 (9) · 1753-1761

DOI: 10.1002/acn3.70120 ↗

Kurz gefasst

Beobachtungsstudie in der Zeitschrift Annals of Clinical and Translational Neurology, online erschienen am 24.06.2025. Verfasst von Yushan He und 7 weiteren Autor:innen. Beteiligte Einrichtung: Pediatric Intensive Care Unit, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Epileptic Syndromes, Anticonvulsants, Seizures, Febrile. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 25 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Objective

This study aimed to assess the efficacy and safety of using tocilizumab in children with febrile infection‐related epilepsy syndrome (FIRES) and explore tocilizumab‐related changes in interleukin (IL)‐6 levels.

Methods

Patients with FIRES admitted to the Intensive Care Unit (ICU) of Beijing Children's Hospital were retrospectively included and categorized into tocilizumab and control groups based on whether tocilizumab was administered to compare prognostic differences and drug safety. Patients in the tocilizumab group were further classified into response (characterized by ≥ 50% reduction in seizure frequency on electroencephalogram within one‐week post‐treatment) and no‐response groups for intergroup comparison of tocilizumab regimens and clinical outcomes. Serum and CSF IL‐6 levels were collected before and after the first tocilizumab dose to analyze the dynamics.

Results

Of 58 enrolled patients with FIRES, 23 received tocilizumab. The tocilizumab group showed higher rates of consciousness recovery and favorable Pediatric Cerebral Performance Category scores ( p < 0.05). The incidence of post‐FIRES epilepsy was lower in the tocilizumab group ( p < 0.001). The response group (9 patients) received earlier tocilizumab treatment, had shorter mechanical ventilation and ICU durations, and experienced higher consciousness recovery rates ( p < 0.05). Serum IL‐6 levels increased post‐treatment ( p = 0.003), while CSF IL‐6 levels showed a non‐significant decline ( p = 0.080). There was no significant difference in the rates of combined infection, liver function impairment, and total cholesterol elevation between the tocilizumab and control groups ( p > 0.05).

Interpretation

Early tocilizumab administration may improve outcomes in patients with FIRES, with a clinically acceptable safety profile.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedEpileptic SyndromesAnticonvulsantsSeizures, FebrileHumansMaleFemaleChild, PreschoolChildRetrospective StudiesInterleukin-6Infant

Stichwörter der Autor:innen

cytokinesfebrile infection‐related epilepsy syndrome (FIRES)immunotherapysafetytocilizumab

Substanzen

tocilizumabAntibodies, Monoclonal, HumanizedInterleukin-6IL6 protein, humanAnticonvulsants

Autor:innen und Institutionen

  • Pediatric Intensive Care Unit, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.
  • Emergency Department, Beijing Children's Hospital, Capital Medical University, National Center for Children's Health, Beijing, China.

ORCID-Profile: Yushan He, Chaonan Fan, Suyun Qian

Förderung

  • Beijing Municipal Science and Technology Commission, Adminitrative Commission of Zhongguancun Science Park

Zitieren

APA

He, Y., Wu, J., Fan, C., Li, Z., Liu, J., Li, K., Wang, Q., & Qian, S. (2025). Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome. Annals of Clinical and Translational Neurology, 12(9), 1753-1761. https://doi.org/10.1002/acn3.70120

Vancouver

He Y, Wu J, Fan C, Li Z, Liu J, Li K, et al. Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome. Annals of Clinical and Translational Neurology. 2025;12(9):1753-1761. doi:10.1002/acn3.70120

BibTeX
@article{He2025,
  author = {He, Yushan and Wu, Jie and Fan, Chaonan and Li, Zheng and Liu, Jun and Li, Kechun and Wang, Quan and Qian, Suyun},
  title = {Observational Study of Tocilizumab in Children With Febrile Infection‐Related Epilepsy Syndrome},
  journal = {Annals of Clinical and Translational Neurology},
  year = {2025},
  volume = {12},
  number = {9},
  pages = {1753--1761},
  doi = {10.1002/acn3.70120}
}
Kostenlos starten →